dornase


Also found in: Dictionary.

dor·nase

(dōr'nās),
Obsolete contraction of deoxyribonuclease.
See also: streptodornase.

dornase

(1) Deoxyribonuclease I, EC 3.1.21.1.
(2) Deoxy-ribonuclease II, EC 3.1.22.1.

dornase

(dor′nās)
Short for deoxyribonuclease.

dornase alfa

An enzyme that lessens the viscosity of sputum by cleaving DNA deposited in it. It is used to treat patients with cystic fibrosis, who have exceptionally thick pulmonary secretions that are hard to expectorate.

pancreatic dornase

Dornase prepared from beef pancreas, used to loosen thick pulmonary secretions.
References in periodicals archive ?
Biopharmaceutical startup JHL Biotech (Stock Code:6540.TWO) disclosed on Wednesday that it has filed a Phase 1 Clinical Trial Application with the Dutch Healthcare Authority for its planned dornase alfa biosimilar, JHL1922, for the improvement of pulmonary function in cystic fibrosis patients.
* Prescribe inhaled dornase alpha and inhaled tobramycin for maintenance pulmonary treatment of moderate to severe cystic fibrosis (CF).
He was on chronic antimicrobial therapy (inhaled colistin and oral azithromycin), as well as inhaled salbutamol, inhaled corticosteroids, dornase alfa, pancreatic enzymes, domperidone, omeprazole, PEG 3350, multivitamins including Vitamins D and K, insulin, ursodeoxycolic acid, furosemide and amilioride.
103532 Pulmozyme (dornase alfa) Inhalation Solution MACMIS ID #17309, FDA.GOV (Apr.
Other medications included dexamethasone, bumetanide, pantoprazole, dornase, and insulin.
(1) Treatment of the pulmonary involvement typically includes inhaled medications [eg, hypertonic saline, tobramycin (an antibiotic), and dornase alfa (a mucolytic)], systemic antibiotics, airway clearance, and exercise.
Acetylcysteine (Mucomyst) and guaifenesin are also helpful, but dornase alfa (Pulmozyme) is not indicated in non-CF patients and was actually harmful in one study.
The purpose of this article is to give a brief overview of how the drug dornase alfa (Pulmozyme (R), Genentech) affects CF, as well as how it is administered, its side effects and case studies.
For example, in children there is 16-20% adherence recorded for dietary supplementation but up to 67-84% for dornase alpha (Modi et al 2006).
-- Sales of legacy products, including growth hormone, cardiovascular products and Pulmozyme(R) (dornase alfa, recombinant) Inhalation Solution, increased 5 percent to $180.9 million from $171.8 million in the second quarter of 2003.
Dornase alfa (Pulmozyme) treatment reduced exacerbations in healthy cystic fibrosis patients who were 6-10 years old.
Possibly the most innovative drug to win FDA approval last year was Genentech Inc.'s dornase alfa, which was what Hussar described as the first major advance for cystic fibrosis patients in 30 years.